Measles Out break – Japan
From 1 January through 20 May 2018, 161 cases of measles were diagnosed, including 145 (90%) laboratory-confirmed cases.
Cases were reported from the following prefectures: Okinawa (88 cases); Aichi (25 cases); Fukuoka (17 cases); Tokyo (11 cases); Saitama (six cases); Ibaraki and Kanagawa (three cases from each prefecture); Yamanashi and Osaka (two cases from eacmh prefecture); and Chiba, Shizuoka, Hyogo, and Yamaguchi (one case from each prefecture).
Okinawa declares end to measles outbreak
Among the total cases, to date, information for 30 cases regarding their isolated measles virus genotype have been received through the national surveillance system; excluding one case with vaccine strain, 25 were genotype D8 and four were genotype B3.
Cases of imported measles continue to occur in Japan. Japan has successfully eliminated endemic measles transmission and sustained this status since March 2015 through both high vaccination coverage and rapid detection of and response to every case of measles. In 2016, routine vaccination coverage was 97% for the first dose (one year of age) and 93% for the second dose (year before entrance to primary school, usually five years of age); serological surveys have confirmed that the proportion of antibody-positive (particle agglutination titer ≥16) individuals aged two years or more has remained at 95% or above nationally.
Measles is a highly contagious viral disease that remains one of the leading causes of mortality among young children globally, despite the availability of a safe and effective vaccine. Transmission from person-to-person is airborne, as well as by direct or indirect contact of secretions (nasal, throat) of an infected person. Initial symptoms, which usually appear 10–12 days after infection, include high fever, runny nose, bloodshot eyes, cough, and tiny white spots on the inside of the mouth. Several days later, a rash develops, starting on the face and upper neck and gradually spreads downwards. A patient is infectious four days before the start of the rash for up to four days after the appearance of the rash.
Key facts about Measels
- Measles is one of the leading causes of death among young children even though a safe and cost-effective vaccine is available.
- Measles vaccination resulted in a 84% drop in measles deaths between 2000 and 2016 worldwide.
- In 2016, about 85% of the world’s children received one dose of measles vaccine by their first birthday through routine health services – up from 72% in 2000.
- During 2000-2016, measles vaccination prevented an estimated 20.4 million deaths making measles vaccine one of the best buys in public health.
- In 2016, there were 89 780 measles deaths globally – marking the first year measles deaths have fallen below 100 000 per year.
The disease remains one of the leading causes of death among young children globally, despite the availability of a safe and effective vaccine. Approximately 89 780 people died from measles in 2016 – mostly children under the age of 5 years.
Measles is caused by a virus in the paramyxovirus family and it is normally passed through direct contact and through the air. The virus infects the respiratory tract , then spreads throughout the body. Measles is a human disease and is not known to occur in animals.
Signs and symptoms
The first sign of measles is usually a high fever, which begins about 10 to 12 days after exposure to the virus, and lasts 4 to 7 days. A runny nose, a cough, red and watery eyes, and small white spots inside the cheeks can develop in the initial stage. After several days, a rash erupts, usually on the face and upper neck. Over about 3 days, the rash spreads, eventually reaching the hands and feet. The rash lasts for 5 to 6 days, and then fades. On average, the rash occurs 14 days after exposure to the virus (within a range of 7 to 18 days).
Most measles-related deaths are caused by complications associated with the disease. Serious complications are more common in children under the age of 5, or adults over the age of 30. The most serious complications include blindness, encephalitis (an infection that causes brain swelling), severe diarrhoea and related dehydration, ear infections, or severe respiratory infections such as pneumonia. Severe measles is more likely among poorly nourished young children, especially those with insufficient vitamin A, or whose immune systems have been weakened by HIV/AIDS or other diseases.
Who is at risk?
Unvaccinated young children are at highest risk of measles and its complications, including death. Unvaccinated pregnant women are also at risk. Any non-immune person (who has not been vaccinated or was vaccinated but did not develop immunity) can become infected.
Measles is still common in many developing countries – particularly in parts of Africa and Asia. The overwhelming majority (more than 95%) of measles deaths occur in countries with low per capita incomes and weak health infrastructure or in countries experiencing or recovering from a natural disaster or conflict.
The highly contagious virus is spread by coughing and sneezing, close personal contact or direct contact with infected nasal or throat secretions.
The virus remains active and contagious in the air or on infected surfaces for up to 2 hours. It can be transmitted by an infected person from 4 days prior to the onset of the rash to 4 days after the rash erupts.In countries where measles has been largely eliminated, cases imported from other countries remain an important source of infection.
No specific antiviral treatment exists for measles virus.
Severe complications from measles can be avoided through supportive care that ensures good nutrition, adequate fluid intake and treatment of dehydration with WHO-recommended oral rehydration solution. This solution replaces fluids and other essential elements that are lost through diarrhoea or vomiting. Antibiotics should be prescribed to treat eye and ear infections, and pneumonia.
All children diagnosed with measles should receive two doses of vitamin A supplements, given 24 hours apart. This treatment restores low vitamin A levels during measles that occur even in well-nourished children and can help prevent eye damage and blindness. Vitamin A supplements have been shown to reduce the number of deaths from measles by 50%.
Routine measles vaccination for children, combined with mass immunization campaigns in countries with high case and death rates, are key public health strategies to reduce global measles deaths. The measles vaccine has been in use for over 50 years. It is safe, effective and inexpensive. It costs approximately one US dollar to immunize a child against measles.
The measles vaccine is often incorporated with rubella and/or mumps vaccines. It is equally effective in the single or combined form. Adding rubella to measles vaccine increases the cost only slightly, and allows for shared delivery and administration costs.
In 2016, about 85% of the world’s children received 1 dose of measles vaccine by their first birthday through routine health services – up from 72% in 2000. Two doses of the vaccine are recommended to ensure immunity and prevent outbreaks, as about 15% of vaccinated children fail to develop immunity from the first dose.
Content taken from WHO and Outbreak News Today